Insulet Will Unveil Its OmniPod Insulin Management System In August
This article was originally published in The Gray Sheet
Executive Summary
Insulet initially will focus marketing efforts for its OmniPod insulin management system on the approximately one mil. Type 1 diabetics in the U.S. who have resisted insulin pump therapy, the company says
You may also be interested in...
Financings In Brief
Insulet proposes $107 mil. IPO: Maker of the OmniPod insulin management system proposes initial public offering, comprising 6.7 million common stock shares at $14 to $16 each and valued at up to $107 million. Proceeds are tabbed for expansion of manufacturing capacity and marketing activities, plus R&D. About 1,750 U.S. patients with diabetes use OmniPod. Cleared via 510(k) in January 2005 and launched in the United States that October, OmniPod includes a small insulin infusion pump that adheres to the skin and can be worn under clothing, and a handheld, wireless programmer that incorporates a blood glucose meter (1"The Gray Sheet" June 6, 2005, p. 16). The Bedford, Mass., firm generated sales of $3.7 million in 2006 and has an accumulated deficit of $102 million. Underwriters include JP Morgan Securities, Merrill Lynch, Thomas Weisel Partners and Leerink Swann & Company...
Financings In Brief
Insulet proposes $107 mil. IPO: Maker of the OmniPod insulin management system proposes initial public offering, comprising 6.7 million common stock shares at $14 to $16 each and valued at up to $107 million. Proceeds are tabbed for expansion of manufacturing capacity and marketing activities, plus R&D. About 1,750 U.S. patients with diabetes use OmniPod. Cleared via 510(k) in January 2005 and launched in the United States that October, OmniPod includes a small insulin infusion pump that adheres to the skin and can be worn under clothing, and a handheld, wireless programmer that incorporates a blood glucose meter (1"The Gray Sheet" June 6, 2005, p. 16). The Bedford, Mass., firm generated sales of $3.7 million in 2006 and has an accumulated deficit of $102 million. Underwriters include JP Morgan Securities, Merrill Lynch, Thomas Weisel Partners and Leerink Swann & Company...
Animas Looks Forward To Continuous Glucose Monitoring As Market Crowds
Animas' hoped-for launch of the GlucoWatch G3 continuous blood glucose monitoring system in the first half of 2006 will depend upon resolution of issues cited in a February warning letter from FDA